drugset / Trial / NCT01343511

Safety and Efficacy of Stem Cell Therapy in Patients With Autism

NCT01343511

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Autism is one of those disorders in Autism spectrum disorders (ASD), which characterized by social interaction abnormalities, impaired verbal and non-verbal communication, and repetitive, obsessive behavior, while the therapeutic effect of current treatments remains limited progress .Neural hypoperfusion and immune deregulation are the two key pathologies associated with Autism. Human umbilical cord mesenchymal stem cells (hUC-MSCs) and human cord blood mononuclear cells (hCB-MNCs) have been shown to have the ability to modulate the immune response and enhance angiogenesis, suggesting the novel and promising therapeutic strategy. In this study, the safety and efficacy of hUC-MSCs and hCB-MNCs transplantation will be evaluated in patients with Autism.

Timeline

Start
2009-03
Primary completion
2010-06
Completion
2011-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject human cord blood mononuclear cells Cell therapy Intravenous
Subject human umbilical cord mesenchymal stem cells Cell therapy Intravenous

Indications